Rowley Law PLLC is investigating potential securities law violations by SpringWorks Therapeutics, Inc. and its board of directors concerning the proposed acquisition of the company by Merck KGaA.

Merck announced Monday it will acquire U.S. biotech company SpringWorks Therapeutics for $47 per share in cash, valuing the deal at approximately $3.9 billion, according to Reuters. The agreement is ...

Health-care companies rose amid deal activity. Germany's Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology ...